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observations
OPEN LETTER
european regulatory agencies 
should employ full time 
statisticians
We would like to draw attention to what we 
believe is a major deficiency in European 
regulatory agencies that are responsible 
for reviewing applications to market new 
medicines across the whole of the European 
Union. Only agencies in the UK, Germany, 
Sweden, and Austria employ several full time 
statisticians, and a few others employ a single 
statistician. Some agencies that have a major 
role in the European regulatory process, such 
as those of Italy and Spain, do not employ 
any full time statisticians—instead they rely on 
external consultants.
Statistics is central to the design of clinical 
trials and to the interpretation of their results. 
Key regulatory guidelines such as ICH 
(International Conference on Harmonisation 
of Technical Requirements for Registration of 
Pharmaceuticals for Human Use) E3, E9, and 
E10 carry this clear message, as do numerous 
disease specific, clinical guidelines from 
CHMP (Committee for Medicinal Products 
for Human Use). The clinical trial component 
of regulatory submissions can be made up of 
the accumulated data from several thousand 
patients enrolled in several clinical trials. 
Evaluation of the data requires consideration 
of the impact of complex statistical issues 
relating to design of the trial and analysis of 
the data, such as bias in trial design, use of 
multiple end points, missing data, interim 
analysis, subgroup 
analyses, analytical 
technique, and 
selection of statistical 
model.
Decisions to 
approve or deny 
potentially important 
new medicines will 
be based on the 
assessment of these 
dossiers. Unless the 
design and statistical analysis of a trial are 
appropriate, results cannot be considered 
reliable and no confidence can be placed in 
the subsequent clinical interpretation. These 
issues have been recognised by major medical 
journals, which routinely provide a statistical 
review of submitted papers.
Another important role of regulatory 
agencies is to provide scientific advice on 
proposed clinical development programmes 
and general guidance on statistical issues. 
Companies seeking regulatory advice want 
to be confident that the advice they receive 
is based on considerable experience of 
regulatory work and knowledge of acceptable 
methodology. Without permanent statisticians, 
agencies are at risk of giving incomplete 
advice. In particular, innovation may be 
stifled if novel methods that are presented are 
methodologically sound but are disregarded 
because they are poorly understood by 
regulatory advisers.
Statistical review should be conducted by 
those who are professionally expert in the 
area, not by medical assessors with some 
knowledge of statistics. Part time academic 
consultants, regardless of their level of 
expertise and experience, are unlikely to be 
able to devote the time required to carry out 
a thorough assessment of a regulatory dossier 
and of the individual clinical trials contained 
in it. Work of this nature must be carried 
out in an organised and timely fashion by 
experts interacting regularly and in detail with 
experts from other disciplines. Knowledge 
and experience must be carried over from 
assessment to assessment. When necessary, 
assessors must be able to devote sufficient time 
to an assessment to allow them to explore 
issues concerning statistical methods and data 
in real depth.
We believe the current situation is 
unacceptable. These same concerns were 
raised in the 1990s by a working party from 
the Royal Statistical Society (J Royal Stat Soc 
(A) 1991;154:413-9) and were subsequently 
addressed by the UK regulatory agency. All 
agencies who undertake review of applications 
should employ full time statisticians to enable 
competent licensing and labelling decisions. 
We call on the heads of the regulatory 
agencies in the EU that do not have full time 
statisticians in their organisations to rectify this 
as a matter of urgency.
Sara Hughes, chair of PSI (professional UK body of 
statisticians in the pharmaceutical industry) and director 
of statistics, GlaxoSmithKline chair@psiweb.org 
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This letter is also signed by:
Oliver Keene, PSI regulatory subcommittee chair and director of 
statistics, GlaxoSmithKline, UK;
Nigel Howitt, EFSPI president (European Federation of Statisticians 
in the Pharmaceutical Industry) and director of analysis and 
reporting, PRA International;
Kit Roes, EFSPI vice president and vice president, Global Clinical 
Information, Organon Schering-Plough;
Deborah Ashby, professor of medical statistics, Queen Mary, 
University of London, UK;
Mohan Beltangady, vice president and global head statistics, Pfizer;
Professor Sheila M Bird, vice president, Royal Statistical Society 
and Medical Research Council’s Biostatistics Unit, Cambridge, UK;
Catherine Burton, global head and vice president clinical 
information sciences, Novartis;
Marc Buyse, executive director, International Drug Development 
Institute, and associate professor of biostatistics, Hasselt 
University, Belgium;
Simon Day, statistical expert, Roche Products Ltd, UK;
Peter van Ewijk, senior director Biometrics Europe, Genzyme;
Chrissie Fletcher, director and head of international biostatistics, 
Amgen;
Andrew P Grieve, professor of medical statistics, King’s College 
London, UK;
Christiane Guinot, president of the French Society of Statistics and 
for the Biopharmacy and Health Group, France;
David J Hand, president of the Royal Statistical Society and 
professor of statistics, Imperial College London
Rob Hemmings, statistics unit manager, MHRA, UK;
Professor D Holt, immediate past president of the Royal Statistical 
Society, UK;
Ludwig Hothorn, president German region of International 
Biostatistical Society and professor of biostatistics, Leibniz 
University Hannover, Germany;
Peter Jagers, outgoing president of Bernoulli Society and professor 
of mathematical statistics, Chalmers University of Technology and 
Gothenberg University, Sweden;
Niels Keiding, outgoing president of International Statistical 
Institute and professor of biostatistics, University of Copenhagen, 
Denmark;
Pasi Korhonen, SSL chair (Statisticians in the Finnish 
Pharmaceutical Industry) and chief executive officer of StatFinn 
Oy, Finland;
Emmanuel Lesaffre, president of International Society of Clinical 
Biostatistics and professor of biostatistics, Leuven University, 
Belgium;
John A Lewis, visiting professor of statistics, University of 
Newcastle upon Tyne, UK;
Geert Molenberghs, professor of biostatistics, Hasselt University, 
Belgium;
Norbert Neumann, president of BBS (Basel Biometric Section of 
International Biometric Society) and head of biostatistics, Basel 
Roche;
Klaus Juel Olsen, president of Danish Society for Biopharmaceutical 
Statistics, Denmark;
Gonnie van Osta, EFSPI Council and chair of working group, 
Pharmaceutical Statistics and Data Management, Netherlands;
Stuart Pocock, professor of medical statistics, London School of 
Hygiene and Tropical Medicine, UK;
Frank Rockhold, senior vice president drug development sciences, 
GlaxoSmithKline;
Andrea Rossi, secretary of the co-ordination committees of BIAS 
(Biometristi dell’Industria Farmaceutica) and head of statistics and 
medical Writing, Eli Lilly Italy;
Stephen Senn, professor of statistics, University of Glasgow, UK;
Theo Stijnen, professor of medical statistics, University of Leiden, 
Netherlands;
Michael Væth, professor of biostatistics, University of Aarhus, 
Denmark;
Stig Johan Wiklund, president of the Swedish Society for Medical 
Statistics, Sweden;
Josephine Wolfram, associate director of biostatistics, Astellas 
Pharma Europe
Responses to this letter are invited via the BMJ or via email to 
chair@psiweb.org
